Cargando…

The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine

Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcitabine, are mediated through enhanced antitumor immune responses. The objective of this study was to use material from a randomized clinical trial to evaluate whether patients with preexisting immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stovgaard, Elisabeth S, Asleh, Karama, Riaz, Nazia, Leung, Samuel, Gao, Dongxia, Nielsen, Lise B, Lænkholm, Anne-Vibeke, Balslev, Eva, Jensen, Maj-Britt, Nielsen, Dorte, Nielsen, Torsten O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118411/ https://www.ncbi.nlm.nih.gov/pubmed/34026336 http://dx.doi.org/10.1080/2162402X.2021.1924492

Ejemplares similares

Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial
por: Shenasa, Elahe, et al.
Publicado: (2022)

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications
por: Asleh, Karama, et al.
Publicado: (2022)

Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer
por: Asleh, Karama, et al.
Publicado: (2021)

Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine
por: Jørgensen, Charlotte LT, et al.
Publicado: (2013)

The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients
por: Jensen, Maj-Britt, et al.
Publicado: (2020)

Cytokeratin on Frozen Sections of Sentinel Node May Spare Breast Cancer Patients Secondary Axillary Surgery
por: Stovgaard, Elisabeth Specht, et al.
Publicado: (2012)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
por: Nielsen, Kåre, et al.
Publicado: (2023)

Advances in sarcoma diagnostics and treatment
por: Dancsok, Amanda R, et al.
Publicado: (2016)

The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer
por: Jensen, Maj-Britt, et al.
Publicado: (2018)

Prognostic Significance of CSF-1R Expression in Early Invasive Breast Cancer
por: Riaz, Nazia, et al.
Publicado: (2021)

Phospho-Ser(784)-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer
por: Zhu, Cuige, et al.
Publicado: (2020)

Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial
por: Skriver, Signe Korsgaard, et al.
Publicado: (2020)

TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
por: Jørgensen, Charlotte Levin Tykjær, et al.
Publicado: (2014)

Automated Quantification of sTIL Density with H&E-Based Digital Image Analysis Has Prognostic Potential in Triple-Negative Breast Cancers
por: Thagaard, Jeppe, et al.
Publicado: (2021)

Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints
por: Chafe, Shawn C., et al.
Publicado: (2021)

Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes
por: Asleh, Karama, et al.
Publicado: (2022)

Dual HER2 blockade in the first-line treatment of metastatic breast cancer - A retrospective population-based observational study in Danish patients
por: Christensen, Thomas, et al.
Publicado: (2020)

Recent Advances in Optimizing Radiation Therapy Decisions in Early Invasive Breast Cancer
por: Riaz, Nazia, et al.
Publicado: (2023)

A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
por: Kümler, Iben, et al.
Publicado: (2015)

Docetaxel/gemcitabine: Various toxicities: 4 case reports
Publicado: (2021)

First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG
por: Celik, Alan, et al.
Publicado: (2022)

A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022)

Clinical and molecular characteristics of triple-negative breast cancer patients in Northern Israel: single center experience
por: Asleh-Aburaya, Karama, et al.
Publicado: (2015)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

TIM-3 expression in breast cancer
por: Burugu, Samantha, et al.
Publicado: (2018)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
por: Joensuu, H., et al.
Publicado: (2010)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
por: Dickson, Mark A., et al.
Publicado: (2015)

Combination of gemcitabine and docetaxel: a regimen overestimated in refractory metastatic osteosarcoma?
por: Xu, Jie, et al.
Publicado: (2018)

Retrospective evaluation of the role of gemcitabine‐docetaxel in well‐differentiated and dedifferentiated liposarcoma
por: Thirasastr, Prapassorn, et al.
Publicado: (2022)

CD8(+ )lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer
por: Liu, Shuzhen, et al.
Publicado: (2012)

Somatic health care professionals’ stigmatization of patients with mental disorder: a scoping review
por: Sølvhøj, Ida Nielsen, et al.
Publicado: (2021)

Effects of a randomized controlled intervention trial on return to work and health care utilization after long-term sickness absence
por: Momsen, Anne-Mette H., et al.
Publicado: (2016)

Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis
por: Lee, Ha-young, et al.
Publicado: (2012)

Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer
por: Li, Fenghu, et al.
Publicado: (2019)

Gemcitabine and Docetaxel Combination Chemotherapy Induced Dermatomyositis Associated with Hand-Foot Syndrome
por: Kawada, Mayuko, et al.
Publicado: (2021)

Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival
por: Maj-Hes, Agnieszka, et al.
Publicado: (2021)

Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration
por: Liu, Shuzhen, et al.
Publicado: (2014)

Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene
por: Kümler, Iben, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bn5p5eu4l7ov1p24d6ll1dchjq